Travere Therapeutics (TVTX) Cash from Operations Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 37.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 16.64% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -7.60% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 34.32% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 25.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.76% |
| Dec 31, 2025 | 40.80% |
| Sep 30, 2025 | 29.18% |
| Jun 30, 2025 | 28.77% |
| Mar 31, 2025 | 8.63% |
| Dec 31, 2024 | 31.60% |
| Sep 30, 2024 | -49.27% |
| Jun 30, 2024 | -101.74% |
| Mar 31, 2024 | -64.99% |
| Dec 31, 2023 | -66.81% |
| Sep 30, 2023 | -164.08% |
| Jun 30, 2023 | -100.18% |
| Mar 31, 2023 | -50.13% |
| Dec 31, 2022 | -157.51% |
| Sep 30, 2022 | -86.78% |
| Jun 30, 2022 | -24.42% |
| Mar 31, 2022 | -39.24% |
| Dec 31, 2021 | -191.52% |
| Sep 30, 2021 | 117.04% |
| Jun 30, 2021 | 63.29% |
| Mar 31, 2021 | -21.57% |
| Dec 31, 2020 | -153.24% |
| Sep 30, 2020 | 2.81% |
| Jun 30, 2020 | -47.06% |
| Mar 31, 2020 | -104.54% |
| Dec 31, 2019 | 19.13% |
| Sep 30, 2019 | -71.57% |
| Jun 30, 2019 | -89.35% |
| Mar 31, 2019 | -79.10% |
| Dec 31, 2018 | -0.12% |
| Sep 30, 2018 | -93.78% |
| Jun 30, 2018 | -32.84% |
| Mar 31, 2018 | -30.73% |
| Dec 31, 2017 | 54.55% |
| Sep 30, 2017 | 33.88% |
| Jun 30, 2017 | 35.31% |
| Mar 31, 2017 | 29.70% |
| Dec 31, 2016 | -0.38% |
| Mar 31, 2016 | 7.99% |